In The News
Test
Test
I’m afraid AI can’t do that: Law firms say smart tech uses limited
Holden dealers reject GM’s bleak alternate reality in class action
Lawyer’s defamation case fails serious harm test, judge finds
Nine, News Corp defeat defamation suits over Central Coast crime coverage
Zip offered Firstmac $4M to settle trade mark suit
High Court rejects Qantas appeal in ground crew sacking case
High Court to rule on reach of workplace law in high-stakes Qantas case
Mosaic Brands boss told GM paying $275K bonus would land him in jail, suit says

Regenerative medicine company Mesoblast has hit back at a shareholder class action over its Remestemcel-L treatment for COVID-19, saying that some group members are barred from bringing claims because of a settlement reached in a US class action.

Subscribe to Lawyerly to access this article.

Already a subscriber?
Lost your password?

For information on rights and reprints, contact subscriptions@lawyerly.com.au